[{"id":"5895dd46-f4f2-46c6-9499-4596f2c29417","acronym":"","url":"https://clinicaltrials.gov/study/NCT06011772","created_at":"2023-08-25T15:08:32.780Z","updated_at":"2025-02-25T14:03:46.296Z","phase":"Phase 1","brief_title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06011772","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/04/2025","primary_completion_date":" 12/04/2025","study_txt":" Completion: 12/04/2026","study_completion_date":" 12/04/2026","last_update_posted":"2025-02-19"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"d479d7a5-69ba-49e5-93fa-ae230286eb90","acronym":"CL1-95029-001","url":"https://clinicaltrials.gov/study/NCT05162755","created_at":"2021-12-17T17:31:24.245Z","updated_at":"2025-02-25T14:02:39.100Z","phase":"Phase 1","brief_title":"S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers","source_id_and_acronym":"NCT05162755 - CL1-95029-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026) • S95029 • Sym021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 06/19/2025","study_completion_date":" 06/19/2025","last_update_posted":"2025-02-19"},{"id":"3641271b-5a0e-409d-997b-5bc0800249e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056024","created_at":"2023-09-28T15:10:33.953Z","updated_at":"2025-02-25T14:18:20.983Z","phase":"Phase 1","brief_title":"A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus","source_id_and_acronym":"NCT06056024","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 05/26/2027","primary_completion_date":" 05/26/2027","study_txt":" Completion: 05/26/2027","study_completion_date":" 05/26/2027","last_update_posted":"2025-02-18"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"ab1e1b4a-5cc0-492c-9676-f254993a91a1","acronym":"ETCTN Study 10166","url":"https://clinicaltrials.gov/study/NCT03600701","created_at":"2021-01-18T17:42:08.981Z","updated_at":"2025-02-25T14:15:13.480Z","phase":"Phase 2","brief_title":"Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03600701 - ETCTN Study 10166","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • KRAS • BRAF • ALK","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2025","study_completion_date":" 07/17/2025","last_update_posted":"2025-02-17"},{"id":"743006a6-c939-4023-8010-4e3aee085ae3","acronym":"E7386-J081-102","url":"https://clinicaltrials.gov/study/NCT04008797","created_at":"2022-06-28T02:54:50.954Z","updated_at":"2025-02-25T15:18:13.404Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","source_id_and_acronym":"NCT04008797 - E7386-J081-102","lead_sponsor":"Eisai Inc.","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386"],"overall_status":"Recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-11"},{"id":"83a4cc91-840b-45a5-8084-819f697c1e10","acronym":"CA209-8LC","url":"https://clinicaltrials.gov/study/NCT03711058","created_at":"2021-01-18T18:11:36.282Z","updated_at":"2025-02-25T14:27:43.047Z","phase":"Phase 1/2","brief_title":"Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer","source_id_and_acronym":"NCT03711058 - CA209-8LC","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 06/14/2022","primary_completion_date":" 06/14/2022","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-13"},{"id":"9dd1dfec-0aa4-4556-89c3-d62638f6b981","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761914","created_at":"2021-01-18T18:29:09.264Z","updated_at":"2025-02-25T16:08:40.101Z","phase":"Phase 1/2","brief_title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","source_id_and_acronym":"NCT03761914","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" HER-2 • KRAS • PGR • WT1 • BRCA • MUC16","pipe":" | ","alterations":" HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation","tags":["HER-2 • KRAS • PGR • WT1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2024-11-19"},{"id":"cc1de029-14f4-4d2a-b95a-10946f2e3471","acronym":"PRELUDE-1","url":"https://clinicaltrials.gov/study/NCT04854213","created_at":"2021-04-22T21:53:13.015Z","updated_at":"2025-02-25T16:32:25.361Z","phase":"","brief_title":"PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)","source_id_and_acronym":"NCT04854213 - PRELUDE-1","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-11-07"},{"id":"76a5691d-3c36-403e-ae0a-2107bdb5f547","acronym":"LEAP-017","url":"https://clinicaltrials.gov/study/NCT04776148","created_at":"2021-03-01T13:52:36.340Z","updated_at":"2025-02-25T13:35:46.773Z","phase":"Phase 3","brief_title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","source_id_and_acronym":"NCT04776148 - LEAP-017","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 480","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2024-10-29"},{"id":"285e0fae-6b50-4026-b6af-15e5137223d2","acronym":"ZWI-ZW25-201","url":"https://clinicaltrials.gov/study/NCT03929666","created_at":"2021-01-18T19:21:37.373Z","updated_at":"2024-07-02T16:34:37.769Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","source_id_and_acronym":"NCT03929666 - ZWI-ZW25-201","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2 • KRAS • BRAF • NRAS • RAS","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-06-06"},{"id":"6724b39f-08dd-46d5-950d-1b4b715f5e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT05061017","created_at":"2021-09-29T11:53:50.927Z","updated_at":"2024-07-02T16:34:58.857Z","phase":"Phase 2","brief_title":"Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)","source_id_and_acronym":"NCT05061017","lead_sponsor":"Diwakar Davar","biomarkers":" KRAS • BRAF • ALK • MET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • cyclophosphamide intravenous • pixatimod (PG545)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 02/05/2024","primary_completion_date":" 02/05/2024","study_txt":" Completion: 03/18/2024","study_completion_date":" 03/18/2024","last_update_posted":"2024-06-04"},{"id":"40f5121b-bb06-4c08-8167-45765aada070","acronym":"KCP-8602-801","url":"https://clinicaltrials.gov/study/NCT02649790","created_at":"2021-01-17T17:34:58.356Z","updated_at":"2024-07-02T16:35:00.978Z","phase":"Phase 1/2","brief_title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","source_id_and_acronym":"NCT02649790 - KCP-8602-801","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • dexamethasone • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 277","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-24"},{"id":"f7adec30-958d-4721-9a82-00722f4075ec","acronym":"PULSE","url":"https://clinicaltrials.gov/study/NCT03992456","created_at":"2021-01-18T19:37:42.598Z","updated_at":"2024-07-02T16:35:02.247Z","phase":"Phase 2","brief_title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","source_id_and_acronym":"NCT03992456 - PULSE","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-21"},{"id":"081658f6-dc5c-4209-b44c-5446bf4825c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03442569","created_at":"2021-01-18T16:58:41.837Z","updated_at":"2025-02-25T14:38:08.450Z","phase":"Phase 2","brief_title":"PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC","source_id_and_acronym":"NCT03442569","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" KRAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 09/21/2020","primary_completion_date":" 09/21/2020","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2024-05-14"},{"id":"06c95d25-232d-4edf-bad2-62ebafe8d024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04474470","created_at":"2021-01-18T21:29:42.332Z","updated_at":"2024-07-02T16:35:04.621Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer","source_id_and_acronym":"NCT04474470","lead_sponsor":"TyrNovo Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • NT219"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 05/08/2024","primary_completion_date":" 05/08/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-09"},{"id":"f337b20f-bcf2-469a-aab5-14a60c90ec2d","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT04256707","created_at":"2021-01-18T20:41:24.594Z","updated_at":"2024-07-02T16:35:05.435Z","phase":"Phase 1/2","brief_title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","source_id_and_acronym":"NCT04256707 - SPRINT","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • 5-fluorouracil • irinotecan • Xpovio (selinexor) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/14/2020","start_date":" 01/14/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-07"},{"id":"36893d7d-86e8-48f0-a407-ed95796d7b18","acronym":"","url":"https://clinicaltrials.gov/study/NCT05948865","created_at":"2023-07-17T14:08:58.925Z","updated_at":"2024-07-02T16:35:05.955Z","phase":"Phase 1","brief_title":"A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05948865","lead_sponsor":"Conjupro Biotherapeutics, Inc.","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" EGFR mutation • KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SYS6010"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/13/2025","primary_completion_date":" 06/13/2025","study_txt":" Completion: 12/12/2025","study_completion_date":" 12/12/2025","last_update_posted":"2024-05-03"},{"id":"8fbd6e8e-874c-421f-815a-e2f59fd6751e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03146962","created_at":"2021-01-18T15:30:34.393Z","updated_at":"2024-07-02T16:35:06.308Z","phase":"Phase 2","brief_title":"High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies","source_id_and_acronym":"NCT03146962","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 03/29/2017","start_date":" 03/29/2017","primary_txt":" Primary completion: 04/21/2023","primary_completion_date":" 04/21/2023","study_txt":" Completion: 04/21/2023","study_completion_date":" 04/21/2023","last_update_posted":"2024-05-02"},{"id":"f2b35136-f790-410c-b54a-4f61af16101b","acronym":"ZWI-ZW25-101","url":"https://clinicaltrials.gov/study/NCT02892123","created_at":"2021-01-17T17:13:28.525Z","updated_at":"2024-07-02T16:35:08.789Z","phase":"Phase 1","brief_title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","source_id_and_acronym":"NCT02892123 - ZWI-ZW25-101","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" EGFR • HER-2 • KRAS • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion","tags":["EGFR • HER-2 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-18"},{"id":"587353e8-69d4-43ef-a2e4-48bd6a9a08e3","acronym":"NuTide:302","url":"https://clinicaltrials.gov/study/NCT03428958","created_at":"2021-01-19T15:31:48.117Z","updated_at":"2024-07-02T16:35:11.599Z","phase":"Phase 1/2","brief_title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","source_id_and_acronym":"NCT03428958 - NuTide:302","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-03"},{"id":"6adec79d-70e3-4577-bae0-5f0e8b153dfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05678257","created_at":"2023-01-10T14:58:55.263Z","updated_at":"2024-07-02T16:35:11.773Z","phase":"Phase 2","brief_title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05678257","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF • UGT1A1","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • UGT1A1*1*1","tags":["KRAS • BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-03"},{"id":"6599101d-aea2-4fda-beb6-038d37252237","acronym":"","url":"https://clinicaltrials.gov/study/NCT04440735","created_at":"2023-04-26T18:04:49.712Z","updated_at":"2024-07-02T16:35:11.822Z","phase":"Phase 1/2","brief_title":"A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04440735","lead_sponsor":"Kahr Medical","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • DSP-107"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-02"}]